Drug targeting to the diseased liver

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 188-197

  Poelstra, Klaas ^a   Prakash, Jai ^a,b   Beljaars, Leonie ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Drug carriers; Drug targeting; Hepatic inflammation; Hepatocellular carcinoma; Liver fibrosis

Indexed keywords

DRUG CARRIER; DRUG-TARGETING; HEPATIC INFLAMMATION; HEPATOCELLULAR CARCINOMA; LIVER FIBROSIS;

CELLS; DRUG DELIVERY; FUNCTIONAL POLYMERS; LIPOSOMES; NUCLEIC ACIDS; VIRUSES;

CYTOLOGY;

ALBUMIN; ASIALOGLYCOPROTEIN RECEPTOR; CYTOKINE; DRUG CARRIER; FUCOSE; LIPOSOME; MANNOSE; NUCLEIC ACID; POLYMER; PROTEIN;

BILE DUCT; CARCINOMA CELL; CELL TYPE; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOTHELIUM CELL; EPITHELIUM CELL; GENE DELIVERY SYSTEM; GENE TARGETING; HUMAN; KUPFFER CELL; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; MOLECULE; PRIORITY JOURNAL; REVIEW; STELLATE CELL; TARGET CELL; VIRUS;

ANIMALS; BILE DUCTS; DRUG DELIVERY SYSTEMS; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; KUPFFER CELLS; LIVER DISEASES;

EID: 84862683094     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.02.011     Document Type: Review

References (174)

1. J.S. Smith, Z. Xu, A.P. Byrnes, A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells, J. Virol. Methods 147 (2008) 54-60.
2. A. Wieckowska, A.J. McCullough, A.E. Feldstein, Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future, Hepatology 46 (2007) 582-589.
3. V. Thakur, M.R. McMullen, M.T. Pritchard, L.E. Nagy, Regulation of macrophage activation in alcoholic liver disease, J. Gastroenterol. Hepatol. 22 (Suppl. 1) (2007) S53-S56.
4. S.L. Friedman, M.B. Bansal, Reversal of hepatic fibrosis - fact or fantasy? Hepatology 43 (2, Suppl. 1) (2006) S82-S88.
5. H. Robertson, J.A. Kirby, W.W. Yip, D.E.J. Jones, A.D. Burt, Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis, Hepatology 45 (2007) 977-981.
6. I. Fabregat, C. Roncero, M. Fernandez, Survival and apoptosis: a dysregulated balance in liver cancer, Liver Int. 27 (2007) 155-162.
7. P.C.N. Rensen, L.A.J.M. Sliedregt, M. Ferns, E. Kieviet, S.M.W. van Rossenberg, S.H. van Leeuwen, T.J.C. van Berkel, E.A.L. Biessen, Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo, J. Biol. Chem. 276 (2001) 37577-37584.
8. X.-Q. Zhang, X.-L. Wang, P.-C. Zhang, Z.-L. Liu, R.-X. Zhuo, H.-Q. Mao, K.W. Leong, Galactosylated ternary DNA/polyphosphoramidate nanoparticles mediate high gene transfection efficiency in hepatocytes, J. Control. Release 102 (2005) 749-763.
9. M. Singh, M. Ariatti, Targeted gene delivery into HepG2 cells using complexes containing DNA, cationized asialoorosomucoid and activated cationic liposomes, J. Control. Release 92 (2003) 383-394.
10. J. Wu, M.H. Nantz, M.A. Zern, Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications, Front. Biosci. 7 (2002) d717-d725.
11. Y.-T. Wu, W.-T. Jiaang, K.-G. Lin, C.-M. Huang, C.-H. Chang, Y.-L. Sun, K.-H. Fan, W.-C. Hsu, H.-E. Wang, S.-B. Lin, A new N-acetylgalactosamine containing peptide as a targeting vehicle for mammalian hepatocytes via asialoglycoprotein receptor endocytosis, Curr. Drug Deliv. 1 (2004) 119-127.
12. G. Di Stefano, F.P. Colonna, A. Bongini, C. Busi, A. Mattioli, L. Fiume, Ribavirin conjugated with lactosaminated poly-L-lysine. Selective delivery to the liver and increased antiviral activity in mice with viral hepatitis, Biochem. Pharmacol. 54 (1997) 357-363.
13. G. Di Stefano, L. Fiume, M. Baglioni, L. Bolondi, C. Busi, P. Chieco, F. Kratz, F. Manaresi, M. Pariali, A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade, Liver Int. 26 (2006) 726-733.
14. L. Fiume, L. Bolondi, C. Busi, P. Chieco, F. Kratz, M. Lanza, A. Mattioli, G. Di Stefano, Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine, J. Hepatol. 43 (2005) 645-652.
15. R. Duncan, Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt, Adv. Drug Deliv. Rev. 61 (2009) 1131-1148.
16. D.K.F. Meijer, G. Molema, Targeting of drugs to the liver, Semin. Liver Dis. 15 (1995) 202-256.
17. L. Zhu, R.I. Mahato, Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation, Bioconjug. Chem. 21 (2010) 2119-2127.
18. C. Nie, C. Liu, G. Chen, J. Dai, H. Li, X. Shuai, Hepatocyte-targeted psiRNA delivery mediated by galactosylated poly(ethylene glycol)-graft- polyethylenimine in vitro, J. Biomater. Appl. 26 (2011) 255-275.
19. H.J. Haisma, A.R. Bellu, Pharmacological interventions for improving adenovirus usage in gene therapy, Mol. Pharm. 8 (2011) 50-55.
20. D. Descamps, K. Benihoud, Two key challenges for effective adenovirus-mediated liver gene therapy: innate immune responses and hepatocytespecific transduction, Curr. Gene Ther. 9 (2009) 115-127.
21. T.H. Nguyen, N. Ferry, Liver gene therapy: advances and hurdles, Gene Ther. 11 (Suppl. 1) (2004) S76-S84.
22. R.W. Herzog, Recent advances in hepatic gene transfer: more efficacy and less immunogenicity, Curr. Opin. Drug Discov. Dev. 8 (2005) 199-206.
23. J. Mátrai, M.K.L. Chuah, T. VandenDriessche, Preclinical and clinical progress in hemophilia gene therapy, Curr. Opin. Hematol. 17 (2010) 387-392.
24. Y. Kawashita, H. Fujioka, A. Ohtsuru, Y. Kaneda, Y. Kamohara, Y. Kawazoe, S. Yamashita, T. Kanematsu, The efficacy and safety of gene transfer into the porcine liver in vivo by HVJ (Sendai virus) liposome, Transplantation 80 (2005) 1623-1629.
25. A. Follenzi, G. Sabatino, A. Lombardo, C. Boccaccio, L. Naldini, Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors, Hum. Gene Ther. 13 (2002) 243-260.
26. Y. Kaneda, Improvements in gene therapy technologies, Mol. Urol. 5 (2001) 85-89.
27. T. Yamada, Y. Iwasaki, H. Tada, H. Iwabuki, M.K.L. Chuah, T. VandenDriessche, H. Fukuda, A. Kondo, M. Ueda, M. Seno, K. Tanizawa, S. Kuroda, Nanoparticles for the delivery of genes and drugs to human hepatocytes, Nat. Biotechnol. 21 (2003) 885-890.
28. C.M. Kowolik, J.K. Yee, Preferential transduction of human hepatocytes with lentiviral vectors pseudotyped by Sendai virus F protein, Mol. Ther. 5 (2002) 762-769.
29. Y. Iimuro, T. Nishio, T. Morimoto, T. Nitta, B. Stefanovic, S.K. Choi, D.A. Brenner, Y. Yamaoka, Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat, Gastroenterology 124 (2003) 445-458.
30. F. Siller-López, A. Sandoval, S. Salgado, A. Salazar, M. Bueno, J. Garcia, J. Vera, J. Gálvez, I. Hernández, M. Ramos, E. Aguilar-Cordova, J. Armendariz-Borunda, Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis, Gastroenterology 126 (2004) 1122-1133.
31. Y. Lin, W.-F. Xie, Y.-X. Chen, X. Zhang, X. Zeng, H. Qiang, W.-Z. Chen, X.-J. Yang, Z.-G. Han, Z.-B. Zhang, Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes, Liver Int. 25 (2005) 796-807.
32. B.D. Brown, G. Sitia, A. Annoni, E. Hauben, L.S. Sergi, A. Zingale, M.G. Roncarolo, L.G. Guidotti, L. Naldini, In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance, Blood 109 (2007) 2797-2805.
33. S.K. Campos, M.A. Barry, Current advances and future challenges in adenoviral vector biology and targeting, Curr. Gene Ther. 7 (2007) 189-204.
34. S.I. Kim, D. Shin, T.H. Choi, J.C. Lee, G.-J. Cheon, K.-Y. Kim, M. Park, M. Kim, Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I, Mol. Ther. 15 (2007) 1145-1152.
35. X. Yan, F. Kuipers, L.M. Havekes, R. Havinga, B. Dontje, K. Poelstra, G.L. Scherphof, J.A.A.M. Kamps, The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse, Biochem. Biophys. Res. Commun. 328 (2005) 57-62.
36. A. Akinc, W. Querbes, S. De, J. Qin, M. Frank-Kamenetsky, K.N. Jayaprakash, M. Jayaraman, K.G. Rajeev, W.L. Cantley, J.R. Dorkin, J.S. Butler, L. Qin, T. Racie, A. Sprague, E. Fava, A. Zeigerer, M.J. Hope, M. Zerial, D.W.Y. Sah, K. Fitzgerald, M.A. Tracy, M. Manoharan, V. Koteliansky, A. Fougerolles, M.A. Maier, Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms, Mol. Ther. 18 (2010) 1357-1364.
37. K.C. Vickers, B.T. Palmisano, B.M. Shoucri, R.D. Shamburek, A.T. Remaley, Micro- RNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins, Nat. Cell Biol. 13 (2011) 423-433.
38. G. Di Stefano, M. Derenzini, F. Kratz, M. Lanza, L. Fiume, Liver-targeted doxorubicin: effects on rat regenerating hepatocytes, Liver Int. 24 (2004) 246-252.
39. A.M. Di Bisceglie, R.H. Ghalib, F.M. Hamzeh, V.K. Rustgi, Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C, J. Viral Hepat. 14 (2007) 721-729.
40. H. Alter, Viral hepatitis, Hepatology 43 (2, Suppl. 1) (2006) S230-S234.
41. H.R. Rosen, Chronic hepatitis C infection, N. Engl. J. Med. 364 (2011) 2429-2438.
42. J.F.P. Berbée, C.C. van der Hoogt, R. Kleemann, E.F. Schippers, R.L. Kitchens, J.T. van Dissel, I.A.J.M. Bakker-Woudenberg, L.M. Havekes, P.C.N. Rensen, Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in Gram-negative sepsis, FASEB J. 20 (2006) E1560-E1569.
43. Y. Jing, A. Shishkov, B.C. Ponnappa, Inhibition of tumor necrosis factor alpha secretion in rat Kupffer cells by siRNA: in vivo efficacy of siRNA-liposomes, Biochim. Biophys. Acta, Gen. Subj. 1780 (2008) 34-40.
44. N. Enomoto, Y. Takei, S. Yamashina, K. Ikejima, T. Kitamura, N. Sato, Anti-inflammatory strategies in alcoholic steatohepatitis, J. Gastroenterol. Hepatol. 22 (Suppl. 1) (2007) S59-S61.
45. G. Szabo, P. Mandrekar, A. Dolganiuc, Innate immune response and hepatic inflammation, Semin. Liver Dis. 27 (2007) 339-350.
46. K. Otogawa, K. Kinoshita, H. Fujii, M. Sakabe, R. Shiga, K. Nakatani, K. Ikeda, Y. Nakajima, Y. Ikura, M. Ueda, T. Arakawa, F. Hato, N. Kawada, Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis, Am. J. Pathol. 170 (2007) 967-980.
47. H. Jaeschke, T. Hasegawa, Role of neutrophils in acute inflammatory liver injury, Liver Int. 26 (2006) 912-919.
48. M.L. Manzano-Alonso, G. Castellano-Tortajada, Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy, World J. Gastroenterol. 17 (2011) 1531-1537.
49. A. Schroeder, C.G. Levins, C. Cortez, R. Langer, D.G. Anderson, Lipid-based nanotherapeutics for siRNA delivery, J. Intern. Med. 267 (2010) 9-21.
50. P.C.N. Rensen, J.C.E. Gras, E.K. Lindfors, K.W. van Dijk, J.W. Jukema, T.J.C. van Berkel, E.A.L. Biessen, Selective targeting of liposomes to macrophages using a ligand with high affinity for the macrophage scavenger receptor class A, Curr. Drug Discov. Technol. 3 (2006) 135-144.
51. F.L.A. Willekens, J.M. Werre, J.K. Kruijt, B. Roerdinkholder-Stoelwinder, Y.A.M. Groenen-Döpp, A.G. van den Bos, G.J. Bosman, T.J.C. van Berkel, Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors, Blood 105 (2005) 2141-2145.
52. B.N. Melgert, P. Olinga, J.M.S. Van Der Laan, B. Weert, J. Cho, D. Schuppan, G.M.M. Groothuis, D.K.F. Meijer, K. Poelstra, Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats, Hepatology 34 (2001) 719-728.
53. B.N. Melgert, B. Weert, H. Schellekens, D.K.F. Meijer, K. Poelstra, The pharmacokinetic and biological activity profile of dexamethasone targeted to sinusoidal endothelial and Kupffer cells, J. Drug Target. 11 (2003) 1-10.
54. B.N. Melgert, P. Olinga, V.K. Jack, G. Molema, D.K.F. Meijer, K. Poelstra, Dexamethasone coupled to albumin is selectively taken up by rat nonparenchymal liver cells and attenuates LPS-induced activation of hepatic cells, J. Hepatol. 32 (2000) 603-611.
55. J.A.A.M. Kamps, H.W.M. Morselt, P.J. Swart, D.K.F. Meijer, G.L. Scherphof, Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells, Proc. Nat. Acad. Sci. U. S. A. 94 (1997) 11681-11685.
56. L. Beljaars, K. Poelstra, G. Molema, D.K.F. Meijer, Targeting of sugar- and charge-modified albumins to fibrotic rat livers: the accessibility of hepatic cells after chronic bile duct ligation, J. Hepatol. 29 (1998) 579-588.
57. M. Bartsch, A.H. Weeke-Klimp, D.K.F. Meijer, G.L. Scherphof, J.A.A.M. Kamps, Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucleotides targeted in vivo to hepatic endothelial cells, Pharm. Res. 19 (2002) 676-680.
58. Y. Okawa, K. Abe, T. Watanabe, H. Sasaki, M. Suzuki, Production of interleukin-1 activity of Kupffer cells from mice treated with the acidic mannan fraction of bakers' yeast, Biol. Pharm. Bull. 25 (2002) 1506-1508.
59. Y. Higuchi, M. Nishikawa, S. Kawakami, F. Yamashita, M. Hashida, Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells, Int. J. Pharm. 287 (2004) 147-154.
60. P.J. Swart, T. Hirano, M.E. Kuipers, Y. Ito, C. Smit, M. Hashida, M. Nishikawa, L. Beljaars, D.K.F. Meijer, K. Poelstra, Targeting of superoxide dismutase to the liver results in anti-inflammatory effects in rats with fibrotic livers, J. Hepatol. 31 (1999) 1034-1043.
61. N. Ishimoto, T. Nemoto, K. Nagayoshi, F. Yamashita, M. Hashida, Improved antioxidant activity of superoxide dismutase by direct chemical modification, J. Control. Release 111 (2006) 204-211.
62. A. Louvet, F. Teixeira-Clerc, M.N. Chobert, V. Deveaux, C. Pavoine, A. Zimmer, F. Pecker, A. Mallat, S. Lotersztajn, Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating kupffer cell polarization in mice, Hepatology 54 (2011) 1217-1226.
63. Y. Higuchi, S. Kawakami, M. Oka, Y. Yabe, F. Yamashita, M. Hashida, Intravenous administration of mannosylated cationic liposome/NFκB decoy complexes effectively prevent LPS-induced cytokine production in a murine liver failure model, FEBS Lett. 580 (2006) 3706-3714.
64. J. Schümann, D. Wolf, A. Pahl, K. Brune, T. Papadopoulos, N. van Rooijen, G. Tiegs, Importance of Kupffer cells for T-cell-dependent liver injury in mice, Am. J. Pathol. 157 (2000) 1671-1683.
65. S. Seki, Y. Habu, T. Kawamura, K. Takeda, H. Dobashi, T. Ohkawa, H. Hiraide, The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses, Immunol. Rev. 174 (2000) 35-46.
66. P. Opanasopit, M. Nishikawa, F. Yamashita, Y. Takakura, M. Hashida, Pharmacokinetic analysis of lectin-dependent biodistribution of fucosylated bovine serum albumin: a possible carrier for Kupffer cells, J. Drug Target. 9 (2001) 341-351.
67. Y. Takei, A. Maruyama, K. Ikejima, N. Enomoto, S. Yamashina, J.J. Lemasters, N. Sato, Genetic manipulation of sinusoidal endothelial cells, J. Gastroenterol. Hepatol. 22 (Suppl. 1) (2007) S68-S72.
68. N. Toriyabe, Y. Hayashi, M. Hyodo, H. Harashima, Synthesis and evaluation of stearylated hyaluronic acid for the active delivery of liposomes to liver endothelial cells, Biol. Pharm. Bull. 34 (2011) 1084-1089.
69. D. Liu, F. Liu, Y.K. Song, Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin, Biochim. Biophys. Acta-Biomembr. 1235 (1995) 140-146.
70. X. Yan, H.W.M. Morselt, G.L. Scherphof, K. Poelstra, J.A.A.M. Kamps, The role of á2-glycoprotein I in liposome-hepatocyte interaction, Biochim. Biophys. Acta- Biomembr. 1667 (2004) 208-214.
71. B. Romberg, C. Oussoren, C.J. Snel, M.G. Carstens, W.E. Hennink, G. Storm, Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration, Biochim. Biophys. Acta-Biomembr. 1768 (2007) 737-743.
72. T. Ishida, M. Ichihara, X. Wang, H. Kiwada, Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes, J. Control. Release 115 (2006) 243-250.
73. T. Ishida, M. Ichihara, X. Wang, K. Yamamoto, J. Kimura, E. Majima, H. Kiwada, Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes, J. Control. Release 112 (2006) 15-25.
74. K. Sroda, J. Rydlewski, M. Langner, A. Kozubek, M. Grzybek, A.F. Sikorski, Repeated injections of PEG-PE liposomes generate anti-PEG antibodies, Cell. Mol. Biol. Lett. 10 (2005) 37-47.
75. J.-E. Jeng, J.-F. Tsai, L.-Y. Chuang, M.-S. Ho, Z.-Y. Lin, M.-Y. Hsieh, S.-C. Chen, W.-L. Chuang, L.-Y. Wang, M.-L. Yu, C.-Y. Dai, J.-G. Chang, Tumor necrosis factor-α 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma, Neoplasia 9 (2007) 987-992.
76. S. Toffanin, S.L. Friedman, J.M. Llovet, Obesity, inflammatory signaling, and hepatocellular carcinoma - an enlarging link, Cancer Cell 17 (2010) 115-117.
77. S.L. Friedman, Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury, J. Biol. Chem. 275 (2000) 2247-2250.
78. R. Bataller, D.A. Brenner, Liver fibrosis, J. Clin. Invest. 115 (2005) 209-218.
79. S.L. Friedman, Preface. Hepatic fibrosis: pathogenesis, diagnosis, and emerging therapies, Clin. Liver Dis. 12 (2008) xiii-xiv.
80. D. Schuppan, N.H. Afdhal, Liver cirrhosis, Lancet 71 (2008) 838-851.
81. J.P. Iredale, Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ, J. Clin. Invest. 117 (2007) 539-548.
82. M. Pinzani, K. Rombouts, S. Colagrande, Fibrosis in chronic liver diseases: diagnosis and management, J. Hepatol. 42 (Suppl. 1) (2005) S22-S36.
83. S.L. Friedman, Evolving challenges in hepatic fibrosis, Nat. Rev. Gastroenterol. Hepatol. 7 (2010) 425-436.
84. L. Beljaars, G. Molema, B. Weert, H. Bonnema, P. Olinga, G.M.M. Groothuis, D.K.F. Meijer, K. Poelstra, Albumin modified with mannose 6-phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells, Hepatology 29 (1999) 1486-1493.
85. D. Schuppan, Y. Popov, Hepatic fibrosis: from bench to bedside, J. Gastroenterol. Hepatol. 17 (Suppl. 3) (2002) S300-S305.
86. J.P. Iredale, Cirrhosis: new research provides a basis for rational and targeted treatments, BMJ 327 (2003) 143-147.
87. S.L. Friedman, Liver fibrosis - from bench to bedside, J. Hepatol. 38 (Suppl. 1) (2003) S38-S53.
88. L. Beljaars, G. Molema, D. Schuppan, A. Geerts, P.J. De Bleser, B. Weert, D.K.F. Meijer, K. Poelstra, Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor, J. Biol. Chem. 275 (2000) 12743-12751.
89. L. Beljaars, B. Weert, A. Geerts, D.K.F. Meijer, K. Poelstra, The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue, Biochem. Pharmacol. 66 (2003) 1307-1317.
90. L. Beljaars, P. Olinga, G. Molema, P. de Bleser, A. Geerts, G.M.M. Groothuis, D.K.F. Meijer, K. Poelstra, Characteristics of the hepatic stellate cell-selective carriermannose 6-phosphate modified albumin (M6P(28)-HSA), Liver 21 (2001) 320-328.
91. R. Greupink, H.I. Bakker, C. Reker-Smit, A.M. van Loenen-Weemaes, R.J. Kok, D.K.F. Meijer, L. Beljaars, K. Poelstra, Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell, J. Hepatol. 43 (2005) 884-892.
92. R. Greupink, H.I. Bakker, W. Bouma, C. Reker-Smit, D.K.F. Meijer, L. Beljaars, K. Poelstra, The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo, J. Pharmacol. Exp. Ther. 317 (2006) 514-521.
93. R. Greupink, C. Reker-Smit, J.H. Proost, A.M. van Loenen Weemaes, M. de Hooge, K. Poelstra, L. Beljaars, Pharmacokinetics of a hepatic stellate cell-targeted doxorubicin construct in bile duct-ligated rats, Biochem. Pharmacol. 73 (2007) 1455-1462.
94. T. Gonzalo, E.G. Talman, A. van de Ven, K. Temming, R. Greupink, L. Beljaars, C. Reker-Smit, D.K.F. Meijer, G. Molema, K. Poelstra, R.J. Kok, Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology, J. Control. Release 111 (2006) 193-203.
95. T. Gonzalo, L. Beljaars, M. van de Bovenkamp, K. Temming, A.M. van Loenen, C. Reker-Smit, D.K.F. Meijer, M. Lacombe, F. Opdam, G. Kéri, L. Örfi, K. Poelstra, R.J. Kok, Local inhibition of liver fibrosis by specific delivery of a plateletderived growth factor kinase inhibitor to hepatic stellate cells, J. Pharmacol. Exp. Ther. 321 (2007) 856-865.
96. W.I. Hagens, A. Mattos, R. Greupink, A. de Jager-Krikken, C. Reker-Smit, A.M. van Loenen-Weemaes, A.S.H. Gouw, K. Poelstra, L. Beljaars, Targeting 15dprostaglandin J2 to hepatic stellate cells: two options evaluated, Pharm. Res. 24 (2007) 566-574.
97. J. Zhang, Q.-S. Zhang, X.-M. Chen, G.-Y. Tian, Synthesis of a targeting drug for antifibrosis of liver; a conjugate for delivering glycyrrhetin to hepatic stellate cells, Glycoconj. J. 19 (2002) 423-429.
98. J.M. Luk, Q.-S. Zhang, N.P. Lee, J.Y. Wo, P.P. Leung, L.-X. Liu, M.-Y. Hu, K.-F. Cheung, C.-K. Hui, G.K. Lau, S.-T. Fan, Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model, Liver Int. 27 (2007) 548-557.
99. Z. Ye, K. Cheng, R.V. Guntaka, R.I. Mahato, Targeted delivery of a triplex-forming oligonucleotide to hepatic stellate cells, Biochemistry 44 (2005) 4466-4476.
100. Z. Ye, K. Cheng, R.V. Guntaka, R.I. Mahato, Receptor-mediated hepatic uptake of M6P-BSA-conjugated triplex-forming oligonucleotides in rats, Bioconjugate Chem. 17 (2006) 823-830.
101. M. Moreno, T. Gonzalo, R.J. Kok, P. Sancho-Bru, M. van Beuge, J. Swart, J. Prakash, K. Temming, C. Fondevila, L. Beljaars, M. Lacombe, P. van der Hoeven, V. Arroyo, K. Poelstra, D.A. Brenner, P. Ginès, R. Bataller, Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats, Hepatology 51 (2010) 942-952.
102. M.M. van Beuge, J. Prakash, M. Lacombe, R. Gosens, E. Post, C. Reker-Smit, L. Beljaars, K. Poelstra, Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice, J. Pharmacol. Exp. Ther. 337 (2011) 628-635.
103. M.M. van Beuge, J. Prakash, M. Lacombe, E. Post, C. Reker-Smit, L. Beljaars, K. Poelstra, Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632, Pharm. Res. 28 (2011) 2045-2054.
104. Y. Sato, K. Murase, J. Kato, M. Kobune, T. Sato, Y. Kawano, R. Takimoto, K. Takada, K. Miyanishi, T. Matsunaga, T. Takayama, Y. Niitsu, Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone, Nat. Biotechnol. 26 (2008) 431-442.
105. H. Rachmawati, C. Reker-Smit, M.N. Lub-de Hooge, A.M. van Loenen-Weemaes, K. Poelstra, L. Beljaars, Chemical modification of interleukin-10 with mannose 6-phosphate groups yields a liver-selective cytokine, Drug Metab. Dispos. 35 (2007) 814-821.
106. R. Bansal, J. Prakash, E. Post, L. Beljaars, D. Schuppan, K. Poelstra, Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice, Hepatology 54 (2011) 586-596.
107. L.-S. Wang, Y.-W. Chen, D.-G. Li, H.-M. Lu, Arg-gly-asp-mannose-6- phosphate inhibits activation and proliferation of hepatic stellate cells in vitro, World J. Gastroenterol. 12 (2006) 1303-1307.
108. L.J. Elrick, V. Leel, M.G. Blaylock, L. Duncan, M.R. Drever, G. Strachan, K.A. Charlton, M. Koruth, A.J. Porter, M.C. Wright, Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells - a potential mechanism for targeting liver anti-fibrotic therapeutics, J. Hepatol. 42 (2005) 888-896.
109. A. Douglass, K. Wallace, R. Parr, J. Park, E. Durward, I. Broadbent, C. Barelle, A.J. Porter, M.C. Wright, Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury, J. Hepatol. 49 (2008) 88-98.
110. J.E. Adrian, K. Poelstra, G.L. Scherphof, G. Molema, D.K.F. Meijer, C. Reker-Smit, H.W.M. Morselt, J.A.A.M. Kamps, Interaction of targeted liposomes with primary cultured hepatic stellate cells: involvement of multiple receptor systems, J. Hepatol. 44 (2006) 560-567.
111. J.E. Adrian, K. Poelstra, G.L. Scherphof, D.K.F. Meijer, A.M. van Loenen-Weemaes, C. Reker-Smit, H.W.M. Morselt, P. Zwiers, J.A.A.M. Kamps, Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats, J. Pharmacol. Exp. Ther. 321 (2007) 536-543.
112. J.E. Adrian, J.A.A.M. Kamps, G.L. Scherphof, D.K.F. Meijer, A.M. van Loenen- Weemaes, C. Reker-Smit, P. Terpstra, K. Poelstra, A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats, Biochim. Biophys. Acta-Biomembr. 1768 (2007) 1430-1439.
113. J.E. Adrian, J.A.A.M. Kamps, K. Poelstra, G.L. Scherphof, D.K.F. Meijer, Y. Kaneda, Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes, J. Drug Target. 15 (2007) 75-82.
114. S.-L. Du, H. Pan, W.-Y. Lu, J. Wang, J. Wu, J.-Y. Wang, Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats, J. Pharmacol. Exp. Ther. 322 (2007) 560-568.
115. F. Li, J.-Y. Sun, J.-Y. Wang, S.-L. Du, W.-Y. Lu, M. Liu, C. Xie, J.-Y. Shi, Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis, J. Control. Release 131 (2008) 77-82.
116. K. Cheng, Z. Ye, R.V. Guntaka, R.I. Mahato, Enhanced hepatic uptake and bioactivity of type α1(I) collagen gene promoter-specific triplex-forming oligonucleotides after conjugation with cholesterol, J. Pharmacol. Exp. Ther. 317 (2006) 797-805.
117. Q. Yu, R. Shao, H.S. Qian, S.E. George, D.C. Rockey, Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension, J. Clin. Invest. 105 (2000) 741-748.
118. Q. Yu, L.G. Que, D.C. Rockey, Adenovirus-mediated gene transfer to nonparenchymal cells in normal and injured liver, Am. J. Physiol. Gastrointest. Liver Physiol. 282 (2002) G565-G572.
119. K.L. Rudolph, S. Chang, M. Millard, N. Schreiber-Agus, R.A. DePinho, Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery, Science 287 (2000) 1253-1258.
120. L. Yang, C.-C. Chan, O.-S. Kwon, S. Liu, J. McGhee, S.A. Stimpson, L.Z. Chen, W.W. Harrington, W.T. Symonds, D.C. Rockey, Regulation of peroxisome proliferatoractivated receptor-γ in liver fibrosis, Am. J. Physiol. Gastrointest. Liver Physiol. 291 (2006) G902-G911.
121. M. Arias, S. Sauer-Lehnen, J. Treptau, N. Janoschek, I. Theuerkauf, R. Buettner, A.M. Gressner, R. Weiskirchen, Adenoviral expression of a transforming growth factor-β1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats, BMC Gastroenterol. 3 (2003) 29.
122. Z. Qi, N. Atsuchi, A. Ooshima, A. Takeshita, H. Ueno, Blockade of type â transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat, Proc. Nat. Acad. Sci. U. S. A. 96 (1999) 2345-2349.
123. Y. Iimuro, D.A. Brenner, Matrix metalloproteinase gene delivery for liver fibrosis, Pharm. Res. 25 (2008) 249-258.
124. M.G. Rots, D.T. Curiel, W.R. Gerritsen, H.J. Haisma, Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors, J. Control. Release 87 (2003) 159-165.
125. M.H. Schoemaker, M.G. Rots, L. Beljaars, A.Y. Ypma, P.L.M. Jansen, H.J. Haisma, K. Poelstra, H. Moshage, Redirection of PDGF-receptor targeted adenovirus from hepatocytes to activated stellate cells, Hepatology 38 (4, Suppl. 1) (2003) 224A.
126. J. Herrmann, M. Arias, E. Van de Leur, A.M. Gressner, R. Weiskirchen, CSRP2, TIMP-1, and SM22α promoter fragments direct hepatic stellate cell-specific transgene expression in vitro, but not in vivo, Liver Int. 24 (2004) 69-79.
127. F. Li, J.-Y. Wang, Targeted delivery of drugs for liver fibrosis, Expert Opin. Drug Discovery 6 (2009) 531-541.
128. K. Poelstra, D. Schuppan, Targeted therapy of liver fibrosis/cirrhosis and its complications, J. Hepatol. 55 (2011) 726-728.
129. V.I. Reshetnyak, Concept on the pathogenesis and treatment of primary biliary cirrhosis, World J. Gastroenterol. 12 (2006) 7250-7262.
130. S. Matsumura, J. Van de Water, P. Leung, J.A. Odin, K. Yamamoto, G.J. Gores, K. Mostov, A.A. Ansari, R.L. Coppel, Y. Shiratori, M.E. Gershwin, Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis, Hepatology 39 (2004) 1415-1422.
131. M.E. Gershwin, A.A. Ansari, I.R. Mackay, Y. Nakanuma, A. Nishio, M.J. Rowley, R.L. Coppel, Primary biliary cirrhosis: an orchestrated immune response against epithelial cells, Immunol. Rev. 174 (2000) 210-225.
132. S. Reynoso-Paz, P.S.C. Leung, J. Van de Water, A. Tanaka, S. Munoz, N. Bass, K. Lindor, P.J. Donald, R.L. Coppel, A.A. Ansari, M.E. Gershwin, Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis, Hepatology 31 (2000) 24-29.
133. R. Díaz, J.W. Kim, J.-J. Hui, Z. Li, G.P. Swain, K.S.K. Fong, K. Csiszar, P.A. Russo, E.B. Rand, E.E. Furth, R.G. Wells, Evidence for the epithelial to mesenchymal transition in biliary atresia fibrosis, Hum. Pathol. 39 (2008) 102-115.
134. D. Scholten, C.H. Österreicher, A. Scholten, K. Iwaisako, G. Gu, D.A. Brenner, T. Kisseleva, Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice, Gastroenterology 139 (2010) 987-998.
135. Y. Popov, D. Schuppan, Epithelial-to-mesenchymal transition in liver fibrosis: dead or alive? Gastroenterology 139 (2010) 722-725.
136. A.A. Gossard, K.D. Lindor, Development of autoimmune hepatitis in primary biliary cirrhosis, Liver Int. 27 (2007) 1086-1090.
137. A. Nishio, J. Neuberger, M.E. Gershwin, Management of patients with primary biliary cirrhosis. A practical guide, BioDrugs 12 (1999) 159-173.
138. Y. Gong, Z. Huang, E. Christensen, C. Gluud, Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and metaanalysis of randomized clinical trials using Bayesian approach as sensitivity analyses, Am. J. Gastroenterol. 102 (2007) 1799-1807.
139. M. Körner, G.M. Hayes, R. Rehmann, A. Zimmermann, A. Scholz, B. Wiedenmann, L.J. Miller, J.C. Reubi, Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma, J. Hepatol. 45 (2006) 825-835.
140. Y. Popov, E. Patsenker, F. Stickel, J. Zaks, K.R. Bhaskar, G. Niedobitek, A. Kolb, H. Friess, D. Schuppan, Integrin αvβ6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies, J. Hepatol. 48 (2008) 453-464.
141. D. Moradpour, H.E. Blum, Pathogenesis of hepatocellular carcinoma, Eur. J. Gastroenterol. Hepatol. 17 (2005) 477-483.
142. T. Yau, R. Pang, P. Chan, R.T. Poon, Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib, Expert Opin. Pharmacother. 11 (2010) 2187-2198.
143. H. Ahmadzadehfar, A. Sabet, K. Wilhelm, H.J. Biersack, J. Risse, Iodine-131- Lipiodol therapy in hepatic tumours, Methods 55 (2011) 246-252.
144. I. Hyodo, M. Mizuno, G. Yamada, T. Tsuji, Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma, Liver 13 (1993) 80-85.
145. L.W. Seymour, K. Ulbrich, S.R. Wedge, I.C. Hume, J. Strohalm, R. Duncan, N-(2- hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice, Br. J. Cancer 63 (1991) 859-866.
146. P.J. Julyan, L.W. Seymour, D.R. Ferry, S. Daryani, C.M. Boivin, J. Doran, M. David, D. Anderson, C. Christodoulou, A.M. Young, S. Hesslewood, D.J. Kerr, Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine, J. Control. Release 57 (1999) 281-290.
147. L. Fiume, G. Di Stefano, Lactosaminated human albumin, a hepatotropic carrier of drugs, Eur. J. Pharm. Sci. 40 (2010) 253-262.
148. L. Fiume, M. Baglioni, C. Busi, M. Manerba, G. Di Stefano, The enhancement of interstitial transport of a doxorubicin-lactosaminated albumin conjugate by imatinib: in rat hepatocellular carcinoma it is not preferentially higher than that in liver and bone marrow, Eur. J. Pharm. Biopharm. 72 (2009) 630-631.
149. D. Martinez-Fong, J.E. Mullersman, A.F. Purchio, J. Armendariz-Borunda, A. Martinez-Hernandez, Nonenzymatic glycosylation of poly-L-lysine: a new tool for targeted gene delivery, Hepatology 20 (1994) 1602-1608.
150. J.R. Merwin, G.S. Noell, W.L. Thomas, H.C. Chiou, M.E. DeRome, T.D. McKee, G.L. Spitalny, M.A. Findeis, Targeted delivery of DNA using YEE(GalNAcAH)3, a synthetic glycopeptide ligand for the asialoglycoprotein receptor, Bioconjugate Chem. 5 (1994) 612-620.
151. K. Maruyama, F. Iwasaki, T. Takizawa, H. Yanagie, T. Niidome, E. Yamada, T. Ito, Y. Koyama, Novel receptor-mediated gene delivery system comprising
152. L. Mohr, A. Yeung, C. Aloman, D. Wittrup, J.R. Wands, Antibody-directed therapy for human hepatocellular carcinoma, Gastroenterology 127 (5, Suppl. 1) (2004) S225-S231.
153. S. Fiorucci, E. Antonelli, O. Morelli, A. Mencarelli, A. Casini, T. Mello, B. Palazzetti, D. Tallet, P. del Soldato, A. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension, Proc. Nat. Acad. Sci. U. S. A. 98 (2001) 8897-8902.
154. M.R. Loureiro-Silva, G.W. Cadelina, Y. Iwakiri, R.J. Groszmann, A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats, J. Hepatol. 39 (2003) 940-946.
155. D.C. Rockey, Cellular pathophysiology of portal hypertension and prospects for management with gene therapy, Clin. Liver Dis. 5 (2001) 851-865.
156. M. Van de Casteele, A. Omasta, S. Janssens, T. Roskams, V. Desmet, F. Nevens, J. Fevery, In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats, Gut 51 (2002) 440-445.
157. A.X. Zhu, K. Stuart, L.S. Blaszkowsky, A. Muzikansky, D.P. Reitberg, J.W. Clark, P.C. Enzinger, P. Bhargava, J.A. Meyerhardt, K. Horgan, C.S. Fuchs, D.P. Ryan, Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma, Cancer 110 (2007) 581-589.
158. A. Asnacios, L. Fartoux, O. Romano, C. Tesmoingt, S.S. Louafi, T. Mansoubakht, P. Artru, T. Poynard, O. Rosmorduc, M. Hebbar, J. Taieb, Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma. Results of a multicenter phase 2 study, Cancer 112 (2008) 2733-2739.
159. X. Liu, P. Tian, Y. Yu, M. Yao, X. Cao, J. Gu, Enhanced antitumor effect of EGF R-targeted p21WAF-1 and GM-CSF gene transfer in the established murine hepatoma by peritumoral injection, Cancer Gene Ther. 9 (2002) 100-108.
160. T.K.W. Lee, J.-S. Han, S.-T. Fan, Z.-D. Liang, P.-K. Tian, J.-R. Gu, I.O.L. Ng, Gene delivery using a receptor-mediated gene transfer system targeted to hepatocellular carcinoma cells, Int. J. Cancer 93 (2001) 393-400.
161. M.F. Wolschek, C. Thallinger, M. Kursa, V. Rössler, M. Allen, C. Lichtenberger, R. Kircheis, T. Lucas, M. Willheim, W. Reinisch, A. Gangl, E. Wagner, B. Jansen, Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice, Hepatology 36 (2002) 1106-1114.
162. X. Liu, P.-K. Tian, D.-W. Ju, M.-H. Zhang, M. Yao, X.-T. Cao, J.-R. Gu, Systemic genetic transfer of p21WAF-1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex, Cancer Gene Ther. 10 (2003) 529-539.
163. S. Bhattacharya, J.R. Novell, G.M. Dusheiko, A.J. Hilson, R. Dick, K.E. Hobbs, Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma, Cancer 76 (1995) 2202-2210.
164. J.-L. Raoul, E. Boucher, Y. Rolland, E. Garin, Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides, Nat. Rev. Gastroenterol. Hepatol. 7 (2010) 41-49.
165. B. Lambert, K. Bacher, L. Defreyne, Rhenium-188 based radiopharmaceuticals for treatment of liver tumours, Q. J. Nucl. Med. Mol. Imaging 53 (2009) 305-310.
166. H. Maeda, G.Y. Bharate, J. Daruwalla, Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect, Eur. J. Pharm. Biopharm. 71 (2009) 409-419.
167. M.H. Schoemaker, L. Conde de la Rosa, M. Buist-Homan, T.E. Vrenken, R. Havinga, K. Poelstra, H.J. Haisma, P.L.M. Jansen, H. Moshage, Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways, Hepatology 39 (2004) 1563-1573.
168. C.J. Steib, A.L. Gerbes, M. Bystron, M. op den Winkel, J. Härtl, F. Roggel, T. Prüfer, B. Göke, M. Bilzer, Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2), J. Hepatol. 47 (2007) 228-238.
169. A. Mallat, C. Gallois, J. Tao, A. Habib, J. Maclouf, P. Mavier, A.-M. Préaux, S. Lotersztajn, Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/ cyclic AMP pathway and cross-talk with endothelin receptors, J. Biol. Chem. 273 (1998) 27300-27305.
170. D.R. Nelson, Z. Tu, C. Soldevila-Pico, M. Abdelmalek, H. Zhu, Y.L. Xu, R. Cabrera, C. Liu, G.L. Davis, Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect, Hepatology 38 (2003) 859-868.
171. R. Malik, D. Schuppan, Serum fibrosis markers to predict clinical and histological progression in hepatitis C non-responders, Gut 59 (2010) 1312-1313.
172. Y. Popov, D. Schuppan, Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies, Hepatology 50 (2009) 1294-1306.
173. M. Friedrich-Rust, W. Rosenberg, J. Parkes, E. Herrmann, S. Zeuzem, C. Sarrazin, Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis, BMC Gastroenterol. 10 (2010) 103.
174. J. Parkes, P. Roderick, S. Harris, C. Day, D. Mutimer, J. Collier, M. Lombard, G. Alexander, J. Ramage, G. Dusheiko, M. Wheatley, C. Gough, A. Burt, W. Rosenberg, Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease, Gut 59 (2010) 1245-1251.